Navigation Links
Co-Diagnostics, Inc. Announces Pricing of Initial Public Offering
Date:7/12/2017

Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of common stock has been priced at $6.00 per share. Total gross proceeds from the offering will be $7,071,192.

The shares will begin trading on July 12, 2017 on the NASDAQ Capital Market under the ticker symbol "CODX." The underwriters have a 45-day option to purchase up to 176,780 additional shares of common stock from Co-Diagnostics to cover over-allotments, if any. The Company intends to use the net proceeds for the development of tests, expansion of laboratory facilities, in-field test performance evaluation and validation, regulatory filings for diagnostic tests, and for working capital and general corporate purposes.

WallachBeth Capital, LLC and Network1 Financial Securities, Inc. acted as co-book running managers for the offering and ViewTrade Securities, Inc. acted as co-manager.

Co-Diagnostics’ registration statement relating to these securities was declared effective as of July 11, 2017 by the U.S. Securities and Exchange Commission. Copies of the final prospectus may be obtained on the SEC’s website, http://www.sec.gov, and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 100 Wall Street, Suite 6600, New York, NY 10005, by telephone at 646-998-7605, or by email at cap-mkts(at)wallachbeth(dot)com or Network 1 Financial Securities, Inc., Attention: Keith Testaverde, by telephone at 800-886-7007 or by mail at 2 Bridge Avenue, Suite 241, Redbank, NJ 07701.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc. (“Company,” or “CDI,”), a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Read the full story at http://www.prweb.com/releases/2017/07/prweb14503777.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
2. Annual Conference about Technology Solutions for People with Disabilities Announces Program
3. Probiotic Action Announces Probiotics Lead the Digestive Health Market
4. Verenium Announces Preliminary Financial Results For Fiscal 2012
5. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
6. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
7. EAG Announces New General Manager of Release-To-Production (RTP) Division
8. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
9. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a ... biotechnology industries to improve patient outcomes and quality of life, will now be ... are being attributed to new regulatory requirements for all new drug products, including ...
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
Breaking Biology News(10 mins):